JMP Securities Reaffirms “Market Outperform” Rating for Enanta Pharmaceuticals (NASDAQ:ENTA)

Enanta Pharmaceuticals (NASDAQ:ENTA)‘s stock had its “market outperform” rating reaffirmed by analysts at JMP Securities in a research note issued on Tuesday,Benzinga reports. They presently have a $21.00 price target on the biotechnology company’s stock. JMP Securities’ target price would suggest a potential upside of 271.02% from the stock’s current price.

Other equities research analysts have also issued research reports about the company. Robert W. Baird cut their price target on Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday, November 26th. HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Enanta Pharmaceuticals in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $17.25.

Enanta Pharmaceuticals Stock Up 15.5 %

NASDAQ:ENTA traded up $0.76 on Tuesday, hitting $5.66. The stock had a trading volume of 459,046 shares, compared to its average volume of 495,011. Enanta Pharmaceuticals has a 52-week low of $4.71 and a 52-week high of $17.80. The stock has a market cap of $120.73 million, a price-to-earnings ratio of -1.03 and a beta of 0.54. The business’s 50-day simple moving average is $5.94 and its two-hundred day simple moving average is $9.68.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its earnings results on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 171.57%. As a group, equities research analysts anticipate that Enanta Pharmaceuticals will post -5.05 EPS for the current year.

Insider Buying and Selling

In other Enanta Pharmaceuticals news, CEO Jay R. Luly sold 5,142 shares of the stock in a transaction on Friday, December 6th. The shares were sold at an average price of $8.06, for a total transaction of $41,444.52. Following the completion of the transaction, the chief executive officer now owns 801,638 shares in the company, valued at $6,461,202.28. This trade represents a 0.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 13.89% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ENTA. JPMorgan Chase & Co. lifted its stake in shares of Enanta Pharmaceuticals by 53.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 243,628 shares of the biotechnology company’s stock valued at $2,524,000 after purchasing an additional 85,082 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in Enanta Pharmaceuticals by 34.1% during the 4th quarter. Assenagon Asset Management S.A. now owns 192,856 shares of the biotechnology company’s stock valued at $1,109,000 after buying an additional 49,050 shares during the period. Barclays PLC lifted its position in Enanta Pharmaceuticals by 294.2% in the third quarter. Barclays PLC now owns 27,438 shares of the biotechnology company’s stock worth $285,000 after buying an additional 20,478 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Enanta Pharmaceuticals during the third quarter worth $122,000. Finally, Geode Capital Management LLC increased its position in Enanta Pharmaceuticals by 3.1% during the third quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock valued at $4,946,000 after acquiring an additional 14,575 shares during the last quarter. Institutional investors own 94.99% of the company’s stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.